Case Study: COVID-19 Vaccine Development

Siewert S, Kieslich K, Braun M, Dabrock P (2023)

Publication Type: Book chapter / Article in edited volumes

Publication year: 2023

Publisher: Springer Science and Business Media B.V.

Series: SpringerBriefs in Philosophy

Pages Range: 47-53

Abstract

When talking about public participation and the regulatory decision-making process, it is crucial to think about the right time and purpose to involve different stakeholders. The chapter explores circumstantial prerequisites for participatory approaches on the basis of a more recent case study: synthetically produced vaccines against the coronavirus SARS-CoV-2. The COVID-19 pandemic made synthetic biology a global issue—in a way that is unprecedented. Yet, its implementation also poses questions for participation for future vaccine and drug production: How can and should we engage the public on ethical questions of emerging and potentially disruptive technologies during a public health emergency? How do certain focus areas, particularly communication and resources, data management and training, provide valuable avenues in dealing with future emergency applications of SB?

Authors with CRIS profile

Stephanie Siewert Lehrstuhl für Systematische Theologie II (Ethik) Peter Dabrock Lehrstuhl für Systematische Theologie II (Ethik)

Involved external institutions

Universität Wien / University of Vienna

Austria (AT) Rheinische Friedrich-Wilhelms-Universität Bonn

Germany (DE)

How to cite

APA:

Siewert, S., Kieslich, K., Braun, M., & Dabrock, P. (2023). Case Study: COVID-19 Vaccine Development. In (pp. 47-53). Springer Science and Business Media B.V..

MLA:

Siewert, Stephanie, et al. "Case Study: COVID-19 Vaccine Development." Springer Science and Business Media B.V., 2023. 47-53.

BibTeX: Download